In 2020, the company's supplementary application for consistency evaluation of fluloxacillin sodium for injection was accepted by the National Drug Evaluation Center.

In 2019, the company's amoxicillin capsules passed the generic drug consistency evaluation, achieving a breakthrough of 'zero' in Guangxi.

Recently, it has obtained the only approval for the production of amodiaquine products in China, and successfully developed artesunate +SP tablets and artesunate + amodiaquine combined antimalarial drugs.

Successfully imitates a batch of high-tech products such as lactobacinase tablets, xiaoxamycin tablets, roxithromycin tablets and salmon-calcitonin injection.

In 1996, the company continued its research and development of artesunate indications and successfully used artesunate for the treatment of schistosomiasis.

In 1987, Artesunate, a national first-class antimalarial drug, was invented, which was the first successfully invented first-class new drug in China and obtained the national invention patent.